Boehringer Ingelheim RCV and Fresenius Kabi successfully coupled HES to a therapeutic protein in an industrial scale applying Fresenius Kabis HESylation® Technology
Ingelheim, Germany, 11 November 2010 - Through the coupling of Fresenius Kabi’s hydroxyethyl starch (“HES”) to a therapeutic protein, the capability to produce robust HESylated pharmaceuticals on an industrial scale level was successfully demonstrated. Fresenius Kabi provided Boehringer Ingelheim RCV GmbH & Co KG with its HESylation® Technology to manufacture HES conjugated to a therapeutic protein.
The HESylated pharmaceutical deriving from both, the laboratory and the industrial scale were well comparable with regard to quality and process yield. The amount of the HESylated pharmaceutical equalled 30,000 once weekly doses of an already approved long acting second generation product.
Upon this first successful collaboration, Boehringer Ingelheim RCV GmbH & Co KG and Fresenius Kabi Deutschland GmbH will actively evaluate further opportunities to extend the collaboration and to apply HESylation® Technology, respectively.
HESylation® Technology
HESylation® Technology allows a targeted modification
of drugs and their characteristics by site-specific coupling to HES
molecules. HES-coupling enables the modification of key
pharmacological parameters such as absorption, metabolization,
half-life, water solubility and safety.
Fresenius Kabi’s Business Unit HESylation® Technology is a focused team of experienced professionals. With access to customized HES species and dedicated fully equipped R&D and GMP facilities the support for biopharmaceutical product developments are fulfilled at highest standards.
